{
    "clinical_study": {
        "@rank": "67172", 
        "arm_group": {
            "arm_group_label": "Endoscopic evaluation", 
            "description": "The study population contained a broad spectrum of endoscopic disease and clinical activity. At entry to the trial patients had active disease defined by the presence of a modified UCDAI score between 4 and 10.1 Only patients who had a MMCS endoscopy subscale score according to a single central reader (n= 194 of 281 participants) were eligible for assessment in the current study."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study of this study is to assess the responsiveness and validity of CIMS\n      (Central Image Management System)-based endoscopic evaluation of UC (Ulcerative Colitis)\n      clinical disease activity by measuring:\n\n      The responsiveness central reader endoscopic EIs [(Endoscopic Indices) (MMCS (Modified Mayo\n      Clinic endoscopy Subscore), UCEIS (Ulcerative Colitis Endoscopic Index of Severity) MBS\n      (Modified Baron Score)] to clinical change from baseline to week 6 in a prospective trial of\n      a treatment of known efficacy in UC."
        }, 
        "brief_title": "Responsiveness of Endoscopic Evaluation in UC", 
        "completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Ulcerative Colitis", 
        "condition_browse": {
            "mesh_term": [
                "Colitis", 
                "Colitis, Ulcerative", 
                "Ulcer"
            ]
        }, 
        "detailed_description": {
            "textblock": "This study will evaluate the responsiveness central reader based EIs for assessing clinical\n      disease activity. Endoscopic images will be obtained from recent large multicenter\n      randomized clinical trial and assessed using utilizing CIMS readers using EIs (MMCS, UCEIS,\n      MBS) and a VAS (visual analog scale). The primary efficacy endpoint of this trial was\n      clinical and endoscopic remission at week 6, with a secondary endpoint of endoscopic and\n      clinical remission at week 10. For the same subjects, clinical data will be obtained\n      including a modified UCDAI (Ulcerative Colitis Disease Activity Index). Central readers are\n      blinded to clinical scores."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Active ulcerative colitis disease defined by the presence of a modified UCDAI score\n             between 4 and 10\n\n          -  Only patients who had an MMCS endoscopy subscale score according to a single reader\n\n          -  Endoscopic videos recorded for CIMS based central reader assessment\n\n        Exclusion Criteria:\n\n          -  UCDAI score less than 4 and greater than 10"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "The study population contained a broad spectrum of endoscopic and clinical activity.  At\n        entry patients had active disease defined by the presence of a modified UCDAI score\n        between 4 and 10."
            }
        }, 
        "enrollment": {
            "#text": "194", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01960439", 
            "org_study_id": "RP1302"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "disease activity", 
            "central reader", 
            "endoscopic indices"
        ], 
        "lastchanged_date": "October 8, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "London", 
                    "country": "Canada", 
                    "state": "Ontario", 
                    "zip": "N6A 5K8"
                }, 
                "name": "Robarts Clinical Trials Inc."
            }
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_groups": "1", 
        "official_title": "Responsiveness of Endoscopic Evaluation of Ulcerative Colitis Using a Central Reader Based Image Management System", 
        "overall_official": {
            "affiliation": "Western University", 
            "last_name": "Brian Feagan, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Canada: Ethics Review Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Each of 4 central readers will score approximately 130 videos", 
            "measure": "Central Reading", 
            "safety_issue": "No", 
            "time_frame": "2 years"
        }, 
        "reference": [
            {
                "PMID": "23528626", 
                "citation": "Feagan BG, Sandborn WJ, D'Haens G, Pola S, McDonald JW, Rutgeerts P, Munkholm P, Mittmann U, King D, Wong CJ, Zou G, Donner A, Shackelton LM, Gilgen D, Nelson S, Vandervoort MK, Fahmy M, Loftus EV Jr, Panaccione R, Travis SP, Van Assche GA, Vermeire S, Levesque BG. The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis. Gastroenterology. 2013 Jul;145(1):149-157.e2. doi: 10.1053/j.gastro.2013.03.025. Epub 2013 Mar 22."
            }, 
            {
                "PMID": "13260656", 
                "citation": "TRUELOVE SC, WITTS LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J. 1955 Oct 29;2(4947):1041-8."
            }, 
            {
                "PMID": "3317057", 
                "citation": "Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987 Dec 24;317(26):1625-9."
            }, 
            {
                "PMID": "16339095", 
                "citation": "Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005 Dec 8;353(23):2462-76."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01960439"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "The effect size of each endoscopic index will be calculated.", 
            "measure": "Endoscopic Responsiveness of endoscopic index to Clinical Change", 
            "safety_issue": "No", 
            "time_frame": "2 years"
        }, 
        "source": "University of Western Ontario, Canada", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Western Ontario, Canada", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "October 2013"
    }
}